Clinical Trial Detail

NCT ID NCT02182622
Title LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel
Recruitment Withdrawn
Gender male
Phase Phase I
Variant Requirements No
Sponsors Martin Gutierrez
Indications

prostate adenocarcinoma

Therapies

Docetaxel

Sonidegib

Age Groups: adult

No variant requirements are available.